COMPANY

Navega Therapeutics, Inc.

HQ: San Diego, CA source · navegatx.com ↗ · West Coast

Location: San Diego, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

14NIH grants

Funding and NIH signals

SEC Form D raise Raised $1.3M (Form D filed Jan 30, 2026). SEC Form D 0002107977-26-000001 (Jan 30, 2026)
Evidence (1 event)
- Jan 30, 2026 · SEC Form D 0002107977-26-000001
  Name of Issuer: Navega Therapeutics, Inc.; CIK: 2107977; Address: San Diego, CA; Submission type: D; Filing date: 2026-01-30; Industry Group: Biotechnology; Date of First Sale: 2026-01-02; Types of Securities Offered: Security to be acquired; Business combination transaction: false; Total Offering Amount: 2500000; Total Amount Sold: 1300000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 18, 2025 Grant Government grant — SBIR: $297,327 (annual award, as published), announced Sep 18, 2025. Agency: NIH/NIAMS. Source: government award database. source ↗

Funding

Last 2 years.

Sep 18, 2025 Government grant — SBIR: $297,327 (annual award, as published), announced Sep 18, 2025. Agency: NIH/NIAMS. Source: government award database. source ↗

NIH awards 14

Annual award amounts. Total $8.1M.

Jun 19, 2024 NIH award 3U44NS122114-04S1 FY2024: $98,701 awarded for that fiscal year; activity U44 (SBIR); PI ALEMAN GUILLEN, FERNANDO; recipient as written: NAVEGA THERAPEUTICS, INC., SAN DIEGO, CA. Preclinical optimization of source ↗
Jun 18, 2024 NIH award 5U44NS122114-04 FY2024: $1,528,057 awarded for that fiscal year; activity U44 (SBIR); PI ALEMAN GUILLEN, FERNANDO; recipient as written: NAVEGA THERAPEUTICS, INC., SAN DIEGO, CA. Preclinical optimization of source ↗
Jan 29, 2024 NIH award 3U44NS122114-03S1 FY2024: $74,701 awarded for that fiscal year; activity U44 (SBIR); PI ALEMAN GUILLEN, FERNANDO; recipient as written: NAVEGA THERAPEUTICS, INC., SAN DIEGO, CA. Preclinical optimization of source ↗
Sep 22, 2023 NIH award 9SB1NS137964-04 FY2023: $400,000 awarded for that fiscal year; activity SB1 (SBIR); PI MORENO, ANA MARIA; recipient as written: NAVEGA THERAPEUTICS, INC., SAN DIEGO, CA. Advancing precision pain medicines t source ↗
Sep 8, 2023 NIH award 4U44NS122114-03 FY2023: $1,149,467 awarded for that fiscal year; activity U44 (SBIR); PI ALEMAN GUILLEN, FERNANDO; recipient as written: NAVEGA THERAPEUTICS, INC., SAN DIEGO, CA. Preclinical optimization of source ↗
Aug 19, 2022 NIH award 5R44CA239940-03 FY2022: $1,283,183 awarded for that fiscal year; activity R44 (SBIR); PI ALEMAN GUILLEN, FERNANDO; recipient as written: NAVEGA THERAPEUTICS, INC., SAN DIEGO, CA. Treatment of Chemotherapy-I source ↗
May 27, 2022 NIH award 5U44NS122114-02 FY2022: $730,264 awarded for that fiscal year; activity U44 (SBIR); PI ALEMAN GUILLEN, FERNANDO; recipient as written: NAVEGA THERAPEUTICS, INC., SAN DIEGO, CA. Preclinical optimization of a source ↗
May 17, 2022 NIH award 3R44CA239940-02S1 FY2022: $134,086 awarded for that fiscal year; activity R44 (SBIR); PI ALEMAN GUILLEN, FERNANDO; recipient as written: NAVEGA THERAPEUTICS, INC., SAN DIEGO, CA. Supplement to Promote Diver source ↗
Sep 17, 2021 NIH award 1R43NS120410-01A1 FY2021: $275,377 awarded for that fiscal year; activity R43 (SBIR); PI MORENO, ANA MARIA; recipient as written: NAVEGA THERAPEUTICS, INC., SAN DIEGO, CA. Optimization of a Gene Therapy for source ↗
Sep 10, 2021 NIH award 2R44CA239940-02 FY2021: $766,685 awarded for that fiscal year; activity R44 (SBIR); PI ALEMAN GUILLEN, FERNANDO; recipient as written: NAVEGA THERAPEUTICS, INC., SAN DIEGO, CA. Treatment of Chemotherapy-Ind source ↗
Jun 1, 2021 NIH award 1U44NS122114-01 FY2021: $698,171 awarded for that fiscal year; activity U44 (SBIR); PI ALEMAN GUILLEN, FERNANDO; recipient as written: NAVEGA THERAPEUTICS, INC., SAN DIEGO, CA. Preclinical optimization of a source ↗
Feb 7, 2020 NIH award 3R43NS112088-01A1S1 FY2020: $95,050 awarded for that fiscal year; activity R43 (SBIR); PI MORENO, ANA MARIA; recipient as written: NAVEGA THERAPEUTICS, INC., SAN DIEGO, CA. Supplement to Promote Diversity a source ↗
Sep 16, 2019 NIH award 1R43NS112088-01A1 FY2019: $529,006 awarded for that fiscal year; activity R43 (SBIR); PI MORENO, ANA MARIA; recipient as written: NAVEGA THERAPEUTICS, INC., SAN DIEGO, CA. Repression of Sodium Channels via source ↗
Sep 11, 2019 NIH award 1R43CA239940-01 FY2019: $288,284 awarded for that fiscal year; activity R43 (SBIR); PI ALEMAN GUILLEN, FERNANDO; recipient as written: NAVEGA THERAPEUTICS, INC., SAN DIEGO, CA. Treatment of Chemotherapy-Ind source ↗